secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001654954-25-010792
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics receives EPO intention to grant patent for levosimendan in PH-HFpEF through 2040
--------------------------------------------------------------------------------

- EPO intends to grant patent covering TNX-103 (oral levosimendan) and other formulations for PH-HFpEF.
- European patent protection through at least December 2040, with potential SPC extension beyond.
- Patent also covers active metabolites OR1896/OR1855 and combination with other cardiovascular drugs.
- Builds on existing U.S. and Canada patents; supports Phase 3 LEVEL-2 study initiation expected this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495425010792/0001654954-25-010792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495425010792/tennx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-010792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer